Elasmogen

Elasmogen is a clinical-stage biotech pioneering a novel class of biologics called soloMERs, which are single-domain, antibody-like proteins engineered for targeted drug delivery. Its lead candidate, ELN28, is a first-in-class, dual-acting conjugate targeting TNFα and JAK pathways for the treatment of Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition with significant unmet need. The company leverages an 'ADC-inspired' approach to achieve precision immunosuppression, aiming to improve efficacy and safety over existing biologics. Backed by UK and Scottish investors, Elasmogen is positioned to advance its innovative pipeline in immune-mediated diseases.

soloMER™ platform: single-domain, antibody-like protein scaffolds derived from shark IgNARs, engineered for high-affinity targeting and conjugation to therapeutic payloads (e.g., small molecule inhibitors). Enables creation of targeted conjugates with localized drug release via cleavable linkers.

In HS, Elasmogen will compete against approved anti-TNF biologics (e.g., adalimumab) and other emerging therapies. Its differentiation lies in the novel dual-action (TNFα + JAKi) and tissue-targeted delivery. More broadly, its platform competes with other targeted biologic modalities (ADCs, bispecifics) in immuno-oncology and inflammation.